Dimetapp Line Extensions Filling Void Of PPA Product Withdrawals
This article was originally published in The Tan Sheet
Executive Summary
Two new Whitehall-Robins' Dimetapp formulations are debuting at the height of the cough/cold season, replacing phenylpropanolamine-containing remedies withdrawn from the market in November.
You may also be interested in...
AHP Dimetapp, Robitussin PPA Withdrawals Lead To $80 Mil. Charge In 2000
American Home Products recorded an $80 mil. charge in the fourth quarter due to its removal of eight Dimetapp products and one Robitussin item in response to data linking phenylpropanolamine with hemorrhagic stroke, the company said Jan. 25.
Direct-To-OTC Approvals, Line Extensions Replace Switches In 2000
Direct-to-OTC drug introductions and line extensions dominated the list of new product rollouts in 2000. The year marked the first time since 1993 that no Rx-to-OTC switches were approved, although FDA reviewed several switch candidates.
Perrigo PPA Product Withdrawal Costs Could Reach $19 Mil.
FDA's request that drug companies voluntarily withdraw phenylpropanolamine-containing cough/cold remedies and appetite suppressants from the market is expected to have no significant, long-term financial impact on two major private labelers who are now reformulating products.